Andrew J. Souers - Concepedia

Author

Andrew J. Souers

Also Known As

A J Souers, A. J. Souers, A. Souers, A.J. Souers, Andrew J Souers, Andrew J. Souers, Andrew James Souers, Andrew Souers, Souers, A.J., Souers, Andrew,

251

Publications

9.8K

Citations

H-Index

Concepts

All Affiliations

AbbVie (United States)Abbott Fund Virginia Commonwealth University University of California, Berkeley Abbott (United Kingdom)

About

Andrew J. Souers is an author at AbbVie (United States) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	30	5.1K
2	Natural Sciences	10	10	557
3	Engineering	4	4	189
4	Health Sciences	4	4	3K
5	Social Sciences	2	2	87

Andrew J. Souers

Publications

Citations

H-Index

Page 1

	Year	Citations
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Andrew J. Souers, Erwin R. Boghaert, Scott Ackler, Nature Medicine ThrombopoiesisThrombosisHematological MalignancyOncologyAntitumor Activity	2013	2.9K
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy Darren C. Phillips, Michael J. Mitten, Erwin R. Boghaert, Science Translational Medicine Cancer TherapyChemoprevention StrategyBcl-2/bcl-xl/bcl-w Inhibitor Abt-263ImmunologyPharmacotherapy	2015	530
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) H Zhang, J Chen, Sajid Khan Tahir, Cell Death and Disease	2015	427
Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity Zhi‐Fu Tao, Lisa Hasvold, Le Wang, ACS Medicinal Chemistry Letters	2014	328
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Molecular Cancer Therapeutics Hematological MalignancyTumor BiologyMedicineImmunologyPharmacology	2016	307
Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208 Andrew J. Souers, Erwin R. Boghaert, Scott Ackler, ThrombosisMolecular PharmacologyBlood PlateletNat MedMedicine	2013	182
Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X<sub>L</sub>–BAX interaction Tareq Saleh, Valerie J. Carpenter, Liliya Tyutyunyk‐Massey, Molecular Oncology	2020	172
β-Turn mimetic library synthesis: scaffolds and applications Andrew J. Souers, Jonathan A. Ellman Tetrahedron Organic ChemistrySynthesis MethodChemistry	2001	158
Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity Milan Bruncko, Le Wang, George S. Sheppard, Journal of Medicinal Chemistry Drug TargetMcl-1 InhibitorsHigh ThroughputExcellent SelectivityCancer Biology	2015	150
Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor Gang Zhao, Andrew J. Souers, Martin J. Voorbach, Journal of Medicinal Chemistry	2008	139

Page 1